AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18430854 — intervention group
Group type: EXPERIMENTAL
Intervention: MR angiography (MRA)
Number of subjects: 514
Study 18430854 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography (CTA)
Number of subjects: 514
Study 18430854 — intervention group
Group type: COMPARATOR
Intervention: Duplex sonography
Number of subjects: 514
Study 18430854 — intervention group
Group type: COMPARATOR
Intervention: MRA
Number of subjects: 514
Study 16489935 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial sweeping of the membranes (every 48 hours until labour commenced up to 42 weeks of gestation)
Number of subjects: 742
Study 16489935 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial sweeping of the membranes (for nulliparous women)
Number of subjects: 742
Study 16489935 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial sweeping of the membranes (for parous women)
Number of subjects: 742
Study 16489935 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 742
Study 12837902 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 42
Study 12837902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10787361 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg (n = 1380)
Number of subjects: 2763
Study 10787361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1383)
Number of subjects: 2763
Study 10787361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower‐extremity fractures
Number of subjects: 2763
Study 10787361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 2763
Study 10787361 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient surgery
Number of subjects: 2763
Study 10787361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical hospitalization
Number of subjects: 2763
Study 10787361 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 2763
Study 10787361 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 2763
Study 8831313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (ITS)
Number of subjects: 129
Study 8831313 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine (EB)
Number of subjects: 129
Study 1485178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg, 4 mg, or 8 mg, three times per day for 3 days
Number of subjects: 673
Study 1485178 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (all doses)
Number of subjects: 673
Study 6729868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pendulum therapy (2000 cGy in ten fractions)
Number of subjects: 0
Study 6729868 — intervention group
Group type: COMPARATOR
Intervention: Stationary field therapy (2000 cGy in ten fractions)
Number of subjects: 0
Study 31274828 — intervention group
Group type: EXPERIMENTAL
Intervention: CETSOL VR Clinic software
Number of subjects: 76
Study 31274828 — intervention group
Group type: COMPARATOR
Intervention: Conventional simulated role-play in a real clinical environment
Number of subjects: 76
Study 30367673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose vaginal gel
Number of subjects: 70
Study 30367673 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole vaginal gel
Number of subjects: 70
Study 24346164 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel models with varying individual-level variances and correlations across treatment arms
Number of subjects: 0
Study 24346164 — intervention group
Group type: COMPARATOR
Intervention: Multilevel models with fixed individual-level variances and correlations across treatment arms
Number of subjects: 0
Study 24726342 — intervention group
Group type: EXPERIMENTAL
Intervention: 300μg indacaterol
Number of subjects: 60
Study 24726342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21894688 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to Guanyuan (CV 4), Zhongji (CV 3), Sanyinjiao (SP 6), Zigong (EX‐CA 1), and Taixi (KI 3) in the observation group.
Number of subjects: 66
Study 21894688 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) in the observation group.
Number of subjects: 66
Study 18435426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery plus medical therapy
Number of subjects: 1066
Study 18435426 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1066
Study 16406997 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 M potassium chloride (KCl)
Number of subjects: 17
Study 16406997 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 17
Study 15353496 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative delayed-enhancement MRI
Number of subjects: 52
Study 15353496 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dysfunctional segments
Number of subjects: 52
Study 15353496 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural extent of hyperenhancement
Number of subjects: 52
Study 15353496 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously dysfunctional but nonenhancing or minimally hyperenhancing segments
Number of subjects: 52
Study 11419683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 200 mg thrice daily for 5 days
Number of subjects: 100
Study 11419683 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 15 mg/kg/day in three divided doses for 7 days
Number of subjects: 100
Study 9268175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (low molecular weight heparin), given subcutaneously once daily
Number of subjects: 164
Study 9268175 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin, continuous intravenous infusion
Number of subjects: 164
Study 8111817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core 30 mg/day
Number of subjects: 251
Study 8111817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core 60 mg/day
Number of subjects: 251
Study 8111817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core 90 mg/day
Number of subjects: 251
Study 8111817 — intervention group
Group type: COMPARATOR
Intervention: ATN + placebo
Number of subjects: 251
Study 8111817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core (all doses)
Number of subjects: 251
Study 8111817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core
Number of subjects: 251
Study 3103730 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg aminohydroxypropylidene diphosphonate
Number of subjects: 16
Study 934677 — intervention group
Group type: EXPERIMENTAL
Intervention: New variants of the Pinkel treatment scheme
Number of subjects: 33
Study 934677 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 33
Study 31241356 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence training (EmotivaMente)
Number of subjects: 121
Study 31241356 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 28421294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy combined with intravesical chemotherapy (group A)
Number of subjects: 283
Study 28421294 — intervention group
Group type: COMPARATOR
Intervention: Intravesical chemotherapy alone (group B)
Number of subjects: 283
Study 27259298 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic and antihypertensive drug use
Number of subjects: 923
Study 23564304 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based pediatric obesity prevention intervention
Number of subjects: 253
Study 20679904 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ilaprazole
Number of subjects: 235
Study 20679904 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ilaprazole
Number of subjects: 235
Study 20679904 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ilaprazole
Number of subjects: 235
Study 20679904 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole
Number of subjects: 235
Study 19413179 — intervention group
Group type: EXPERIMENTAL
Intervention: PTRA followed by IVBT
Number of subjects: 62
Study 19413179 — intervention group
Group type: COMPARATOR
Intervention: PTRA alone
Number of subjects: 62
Study 16834791 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (2.5 mg kg‐1)
Number of subjects: 75
Study 16834791 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.3 mg kg‐1)
Number of subjects: 75
Study 16834791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (5 microg kg‐1)
Number of subjects: 75
Study 15704320 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeSite Hemodialysis System with 70% isopropyl alcohol as the antimicrobial solution
Number of subjects: 0
Study 15704320 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular vein placement with positioning of the valve on the anterior chest wall
Number of subjects: 0
Study 11697835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capecitabine 1,255 mg/m2 twice daily (two weeks' treatment followed by a one-week rest period)
Number of subjects: 95
Study 11697835 — intervention group
Group type: COMPARATOR
Intervention: Intravenous CMF (cyclophosphamide, methotrexate, 5-fluorouracil) administered every three weeks
Number of subjects: 95
Study 9208260 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 treatment
Number of subjects: 8
Study 9208260 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (before treatment)
Number of subjects: 8
Study 8434830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0
Study 8434830 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 8434830 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 0
Study 8434830 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (prophylactic use)
Number of subjects: 0
Study 3497638 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1 Serono)
Number of subjects: 90
Study 3497638 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study 31305281 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol ± Ivabradine (THR group A)
Number of subjects: 189
Study 31305281 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group B)
Number of subjects: 189
Study 30305092 — intervention group
Group type: EXPERIMENTAL
Intervention: Otic gel containing 1% florfenicol, 1% terbinafine and 0.1% betamethasone acetate applied twice with a one‐week interval
Number of subjects: 286
Study 30305092 — intervention group
Group type: COMPARATOR
Intervention: Suspension containing hydrocortisone aceponate, miconazole and gentamicin administered daily for 5 days
Number of subjects: 286
Study 30305092 — intervention group
Group type: COMPARATOR
Intervention: Both groups (otic gel and suspension)
Number of subjects: 286
Study 26741257 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized movements during unintended coordination tasks
Number of subjects: 0
Study 26741257 — intervention group
Group type: COMPARATOR
Intervention: Unintended interpersonal coordination task with manipulated synchronization and richness
Number of subjects: 0
Study 25588519 — intervention group
Group type: EXPERIMENTAL
Intervention: 5HTT polymorphism (short group)
Number of subjects: 228
Study 25588519 — intervention group
Group type: EXPERIMENTAL
Intervention: 5HTT polymorphism (long group)
Number of subjects: 228
Study 25588519 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 228
Study 22015960 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physician care with care management (n=32)
Number of subjects: 57
Study 22015960 — intervention group
Group type: COMPARATOR
Intervention: Enhanced physician care only (n=25)
Number of subjects: 57
Study 20870116 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (IOL) implantation
Number of subjects: 0
Study 20870116 — intervention group
Group type: COMPARATOR
Intervention: Peripheral corneal relaxing incisions
Number of subjects: 0
Study 18184678 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled heated breathing tube humidifier (ThermoSmart(R))
Number of subjects: 19
Study 18184678 — intervention group
Group type: COMPARATOR
Intervention: Conventional heated humidification
Number of subjects: 19
Study 16720430 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine
Number of subjects: 214
Study 16720430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 15566051 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in after school programs (ASPs)
Number of subjects: 0
Study 15566051 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in after school programs (ASPs) with high emphasis on social skills and character development
Number of subjects: 0
Study 11230037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 708
Study 11230037 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 708
Study 9036753 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 41
Study 9036753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8345370 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with 30 micrograms/kg intravenous (i.v.) alfentanil, 2.5 mg/kg i.v. thiopental, and 0.1 mg/kg i.v. vecuronium, maintained with 0.5 microgram/kg/min alfentanil, nitrous oxide (N2O) 67% in oxygen, and 0.8 microgram/kg/min vecuronium.
Number of subjects: 89
Study 8345370 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy with one of three different treatment modalities (20 to 60 micrograms/kg i.v. alfentanil, 0.5 to 2.0% inspired isoflurane, or 0.05 to 0.15 mg/kg i.v. trimethaphan).
Number of subjects: 89
Study 8345370 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincision EEG‐SEF and LECI values.
Number of subjects: 89
Study 3946979 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate Ca concentration of 7.5 mg/dL
Number of subjects: 12
Study 3946979 — intervention group
Group type: COMPARATOR
Intervention: Dialysate Ca concentration of 5.5 mg/dL
Number of subjects: 12
Study 28812151 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided biopsy sampling (EUS-FNB)
Number of subjects: 70
Study 28812151 — intervention group
Group type: COMPARATOR
Intervention: Fine needle aspiration (EUS-FNA)
Number of subjects: 70
Study 27919256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 302
Study 25330687 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg-norgestimate 250 mcg-ethinyl estradiol 35 microg (Group A)
Number of subjects: 167
Study 25330687 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate 12 mg-ethinyl estradiol 35 microg (Group B)
Number of subjects: 167
Study 25330687 — intervention group
Group type: COMPARATOR
Intervention: Norgestimate 250 mcg-ethinyl estradiol 35 microg (Group C)
Number of subjects: 167
Study 23031562 — intervention group
Group type: EXPERIMENTAL
Intervention: LND + RE (low energy, low CP diet with 50 mg/kg NSP-hydrolysing enzyme)
Number of subjects: 200
Study 23031562 — intervention group
Group type: EXPERIMENTAL
Intervention: HND + RE (high energy, high CP diet with 50 mg/kg NSP-hydrolysing enzyme)
Number of subjects: 200
Study 23031562 — intervention group
Group type: EXPERIMENTAL
Intervention: HND (high energy, high CP diet)
Number of subjects: 200
Study 23031562 — intervention group
Group type: COMPARATOR
Intervention: LND (low energy, low CP diet)
Number of subjects: 200
Study 19818694 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 5mg/kg/day
Number of subjects: 56
Study 19818694 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 15mg/kg/day
Number of subjects: 56
Study 19818694 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 56
Study 18338628 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal CONSORT statement
Number of subjects: 0
Study 18338628 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) theory
Number of subjects: 0
Study 16807259 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-positive patients
Number of subjects: 98
Study 16807259 — intervention group
Group type: COMPARATOR
Intervention: NTM-negative patients
Number of subjects: 98
Study 14606738 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Relearning Programme
Number of subjects: 61
Study 14606738 — intervention group
Group type: COMPARATOR
Intervention: Bobath
Number of subjects: 61
Study 10094119 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (MET)
Number of subjects: 16
Study 10094119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 10094119 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (MET) and Graded Maximal Exercise Test (GXT)
Number of subjects: 16
Study 8665377 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets (ITBN)
Number of subjects: 11000
Study 1890364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of heat‐killed Mycobacterium leprae and BCG
Number of subjects: 29000
Study 1890364 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 29000
Study 6388916 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (freon propellant device - Rhinocort) 400 micrograms daily
Number of subjects: 118
Study 6388916 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (water solution in mechanical pump spray) 400 micrograms daily
Number of subjects: 118
Study 6388916 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (water solution in mechanical pump spray) 200 micrograms daily
Number of subjects: 118
Study 28961958 — intervention group
Group type: EXPERIMENTAL
Intervention: Online life review therapy with online counseling
Number of subjects: 58
Study 28961958 — intervention group
Group type: EXPERIMENTAL
Intervention: Online life review therapy with online peer support
Number of subjects: 58
Study 28961958 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 58
Study 30355101 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neutrophil levels with ICAS
Number of subjects: 1034
Study 30355101 — intervention group
Group type: COMPARATOR
Intervention: Lower neutrophil levels without ICAS
Number of subjects: 1034
Study 30355101 — intervention group
Group type: EXPERIMENTAL
Intervention: Any hemorrhage at 90 days
Number of subjects: 1034
Study 25846401 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved abutments (experimental)
Number of subjects: 26
Study 25846401 — intervention group
Group type: COMPARATOR
Intervention: Conventional abutments (control)
Number of subjects: 26
Study 24713181 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 108
Study 21688195 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA-guided ultrafiltration
Number of subjects: 135
Study 21688195 — intervention group
Group type: COMPARATOR
Intervention: Clinical-guided ultrafiltration
Number of subjects: 135
Study 20559467 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-conducted vestibular evoked myogenic potentials (AC-VEMPs)
Number of subjects: 41
Study 20559467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-conducted vestibular evoked myogenic potentials (BC-VEMPs)
Number of subjects: 41
Study 20559467 — intervention group
Group type: COMPARATOR
Intervention: Air-bone gap (ABG)
Number of subjects: 41
Study 20559467 — intervention group
Group type: COMPARATOR
Intervention: Bone-conduction 4-frequency pure tone average (4-PTA)
Number of subjects: 41
Study 20559467 — intervention group
Group type: COMPARATOR
Intervention: Air-conducted 4-frequency pure tone average (4-PTA)
Number of subjects: 41
Study 17537772 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam macrolide combination therapy
Number of subjects: 451
Study 17537772 — intervention group
Group type: COMPARATOR
Intervention: Beta-lactam alone monotherapy
Number of subjects: 451
Study 17537772 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched groups (27 patients each from monotherapy and combination therapy)
Number of subjects: 451
Study 17537772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 451
Study 16612523 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 50
Study 16612523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12002966 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted communication (which combined verbal and computerized communication)
Number of subjects: 79
Study 12002966 — intervention group
Group type: COMPARATOR
Intervention: Verbal communication
Number of subjects: 79
Study 10068095 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon monotherapy (6 months)
Number of subjects: 376
Study 10068095 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon monotherapy (up to 12 months)
Number of subjects: 376
Study 10068095 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin combination therapy (6 months)
Number of subjects: 376
Study 10068095 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV RNA test at week 4
Number of subjects: 376
Study 8830203 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate (50 mg), given 4 times daily for 3 days starting 2 hours after surgery (Trial 1)
Number of subjects: 40
Study 8830203 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate (50 mg), given 4 times daily for 3 days starting 3 hours after surgery (Trial 2)
Number of subjects: 40
Study 8830203 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate (50 mg)
Number of subjects: 40
Study 2187380 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 0
Study 6775298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NGS) 0.75 mg
Number of subjects: 6
Study 6775298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (NGO) 15 mg
Number of subjects: 6
Study 6775298 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 6
Study 31982649 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0